Sanofi News | finanzen.ch

Sanofi Aktie VALOR 699381 / ISIN FR0000120578

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

30.05.25	Biotech Stocks Facing FDA Decision In June 2025 (RTTNews)
30.05.25	Regeneron, Sanofi: COPD Drug Itepekimab Meets Primary Goal In 1 Phase 3 Trial, But Fails In Another (RTTNews)
30.05.25	Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies (GlobeNewswire)
29.05.25	Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs (GlobeNewswire)
27.05.25	Sanofi Buys DR-0201 Myeloid Cell Engager From Dren Bio (RTTNews)
27.05.25	Press Release: Sanofi completes acquisition of DR-0201 (GlobeNewswire)
23.05.25	Sanofi Opens New $130 Mln NJ Offices In Morristown (RTTNews)
22.05.25	Sanofi To Acquire Vigil Neuroscience With Investigational Alzheimer's Drug VG-3927 (RTTNews)
22.05.25	Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline (GlobeNewswire)
19.05.25	Novavax Says FDA Approves BLA For COVID-19 Vaccine Nuvaxovid (RTTNews)
15.05.25	Sanofi: Information concerning the total number of voting rights and shares - April 2025 (GlobeNewswire)
20.09.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old (EN, Sanofi-Aventis)
20.09.24	Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study (EN, Sanofi-Aventis)
12.09.24	Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers (EN, Sanofi-Aventis)
12.09.24	Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers (GlobeNewswire)
11.09.24	Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU (EN, Sanofi-Aventis)
11.09.24	Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study (EN, Sanofi-Aventis)
10.09.24	Media Update: ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies (EN, Sanofi-Aventis)
02.09.24	Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis (EN, Sanofi-Aventis)
26.08.24	Media Update: ERS: New data highlight Sanofi’s scientific innovation and leadership in immune-mediated respiratory diseases (EN, Sanofi-Aventis)
08.08.24	Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant (EN, Sanofi-Aventis)
25.07.24	Press Release: Online availability of Sanofi’s half-year financial report for 2024 (EN, Sanofi-Aventis)
25.07.24	Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded (EN, Sanofi-Aventis)
17.07.24	Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A (EN, Sanofi-Aventis)
03.07.24	Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD (EN, Sanofi-Aventis)
28.06.24	Media Update: Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS (EN, Sanofi-Aventis)
26.06.24	Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM (EN, Sanofi-Aventis)
25.06.24	Media Update: Riliprubart one-year follow-up from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy (EN, Sanofi-Aventis)
25.06.24	Press Release: Availability of the Q2 2024 Aide-mémoire (EN, Sanofi-Aventis)
21.06.24	Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee (EN, Sanofi-Aventis)
21.06.24	Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran (EN, Sanofi-Aventis)
20.06.24	Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa (EN, Sanofi-Aventis)
03.06.24	Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 (EN, Sanofi-Aventis)
01.06.24	Media Update: Sanofi update on Zantac litigation (EN, Sanofi-Aventis)
31.05.24	Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan (EN, Sanofi-Aventis)
31.05.24	Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD (EN, Sanofi-Aventis)
31.05.24	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation (EN, Sanofi-Aventis)
01.12.22	Form 8.3 - The Vanguard Group, Inc.: Sanofi (EQS Group)
10.07.09	Chattem to Webcast Presentation from the Oppenheimer 9th Annual Consumer, Gaming, Lodging & Leisure Conference (Businesswire)
01.06.09	Chattem to Webcast Presentation from William Blair & Company’s 29th Annual Growth Stock Conference (Businesswire)
19.03.09	Genzyme Receives Positive Opinion for European Approval of Renvela for Patients with Kidney Disease (Businesswire)
29.01.09	Fourth Quarter and Fiscal 2008 Results; Chattem Affirms Fiscal 2009 Guidance (Businesswire)
29.01.09	Fourth Quarter and Fiscal 2008 Results; Chattem Affirms Fiscal 2009 Guidance (Businesswire)
13.01.09	Genzyme Reports Strong Fourth-Quarter and 2008 Revenue Growth (Businesswire)
11.12.08	Progress by Genzyme, the Broad Institute and Medicines for Malaria Ventures Toward Developing Drug Candidates for Malaria Highlighted at Tropical Medicine Meeting (Businesswire)
09.12.08	Genzyme Reports Clolar® Data Further Supporting Potential of Product to Treat Adult AML Patients (Businesswire)
05.12.08	FDA Advisory Committee to Discuss Genzyme’s Synvisc-One PMA on Tuesday (Businesswire)
14.11.08	Chattem to Webcast Presentation from the Morgan Stanley Global Consumer & Retail Conference on November 18, 2008 (Businesswire)
10.09.07	Chattem to Webcast Presentation from the A.G. Edwards 2nd Annual Emerging Growth Conference on September 19, 2007 (Businesswire)
07.11.05	President & CEO of Memorial Hospital Joins Chattem, Inc.'s Board of Directors (Businesswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	265.50	2.04 %	K V
Lonza Grp	569.20	1.43 %	K V
Novartis	94.03	1.40 %	K V
Geberit	613.00	0.79 %	K V
Part Grp Hldg	1’102.00	0.78 %	K V
CieFinRichemont	154.85	-0.67 %	K V
Kuehne+Nagel Int	185.05	-0.80 %	K V
ABB	46.54	-1.61 %	K V
Logitech Intl	68.44	-2.34 %	K V
Holcim	91.02	-2.57 %	K V

mehr

31.05.25		Roche-Aktie: Verbesserung von Überlebenschancen mit Brustkrebs-Kandidaten Itovebi
31.05.25		Bayer-Aktie: Was Analysten im Mai vom Papier halten
31.05.25		Mai 2025: Die Expertenmeinungen zur Sanofi-Aktie
31.05.25		Novartis-Aktie: Was Analysten von Novartis erwarten
31.05.25		Analysten sehen für EVOTEC SE-Aktie Luft nach oben
31.05.25		Merck-Aktie: Einschätzungen und Kursziele der Analysten im Mai
30.05.25		Roche-Aktie fester: Positive Daten zu MS-Medikament Fenebrutinib
30.05.25		Sanofi-Studie: Itepekimab erzielt uneinheitliche Ergebnisse - Aktie tiefrot